GALECTO
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical need. Galecto was founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
GALECTO
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2011-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.galecto.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
160.41 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome IPv6 ReCAPTCHA
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
CG Oncology
CG Oncology is a clinical-stage biopharmaceutical company focused on the development of oncolytic immunotherapies to combat cancer.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Janus Henderson Investors
Janus Henderson Investors investment in Series D - Galecto
Hadean Ventures
Hadean Ventures investment in Series D - Galecto
Bristol Myers Squibb
Bristol Myers Squibb investment in Series D - Galecto
Canica
Canica investment in Series D - Galecto
Seventure Partners
Seventure Partners investment in Series D - Galecto
OrbiMed
OrbiMed investment in Series D - Galecto
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Series D - Galecto
EIR Ventures
EIR Ventures investment in Series D - Galecto
Ysios Capital
Ysios Capital investment in Series D - Galecto
Sphera Funds Management
Sphera Funds Management investment in Series D - Galecto
Official Site Inspections
http://www.galecto.com Semrush global rank: 3.49 M Semrush visits lastest month: 4.29 K
- Host name: 567964.cloudwaysapps.com
- IP address: 167.71.79.29
- Location: Amsterdam Netherlands
- Latitude: 52.352
- Longitude: 4.9392
- Timezone: Europe/Amsterdam
- Postal: 1098
More informations about "Galecto"
About Galecto – Galecto, Inc.
Galecto, Inc. Galecto develops small molecules for the treatment of severe diseases, including cancer and fibrosis – for more information see: Products. Galecto Biotech was founded in …See details»
Galecto - Crunchbase Company Profile & Funding
Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. …See details»
Investor Relations | Galecto
Oct 17, 2024 Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on nearly 15 years of research into galectin modulators. By employing our world …See details»
Founders – Galecto, Inc.
FAQs - Galecto
Galecto was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. Where is Galecto’s corporate headquarters? Galecto’s …See details»
Galecto - Contacts, Employees, Board Members, Advisors & Alumni
Organization. Galecto . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies ... Galecto has 23 current employee profiles, including …See details»
Galecto - Funding, Financials, Valuation & Investors - Crunchbase
Galecto is registered under the ticker NASDAQ:GLTO . Their stock opened with $15.00 in its Oct 28, 2020 IPO. Stock Symbol NASDAQ:GLTO ; Valuation at IPO $368.8M; Money Raised at …See details»
Galecto Reports Third Quarter Operating and Financial Results
Sep 30, 2022 BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused …See details»
Galecto - Overview, News & Similar companies | ZoomInfo.com
Who is Galecto. Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 (and the galectin fam ily generally) and LOXL2. …See details»
Annual Reports & Proxies | Galecto
Title Documents; 2023 Annual Report on Form 10-K: Add Files. 2023 Annual Report on Form 10-K 1.4 MBSee details»
Galecto Company Profile - Office Locations, Competitors ... - Craft
Galecto Biotech is a company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer, and inflammation. Its products target galectins or galactoside …See details»
Galecto and PharmAkea merge to create strong clinical-stage …
Jan 7, 2020 Galecto is focused on developing novel drugs for the treatment of fibrosis, inflammation, and other serious human diseases. The company’s products target galectins or …See details»
Galecto, Inc. (GLTO) Stock Price, Quote & News - Stock ... - Stock …
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company’s lead product …See details»
Diseases – Galecto, Inc.
Galecto’s small molecule pipeline targets a key protein involved in the fibrotic process, galectin-3. Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. …See details»
Galecto Announces Clinical Collaboration with Roche for Phase 2 …
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a publicly listed biotechnology company focused on the development of novel treatments for fibrosis and …See details»
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases ...
Nov 1, 2024 Galecto, Inc. faces a significant business risk following its recent strategic shift towards oncology and severe liver diseases, marked by the acquisition of BRM-1420 from …See details»
Ten years of experience with ruxolitinib since approval for ...
22 hours ago INTRODUCTION. Polycythemia vera (PV) is a chronic myeloproliferative neoplasm defined by primary absolute erythrocytosis, bone marrow hypercellularity, and Janus …See details»
News Releases - Galecto
Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211 Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 …See details»
Liver disease – Galecto, Inc.
Liver Disease. Galecto is developing GB1211 as a potential treatment for patients with severe liver diseases. GB1211 is an orally bioavailable first-in-class, potent and high-affinity small …See details»
Pipeline – Galecto, Inc.
Galecto, Inc. develops small molecules for the treatment of cancer and severe liver diseases. The company is built on nearly 15 years of research centering on the role of galectin-3 and the use …See details»